Breast Cancer Research and Treatment

, Volume 178, Issue 1, pp 247–248 | Cite as

The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression

  • Z. StrizovaEmail author
  • J. VachtenheimJr.
  • J. Bartunkova
Letter to the Editor

In HER2-positive breast cancer (BC), the standard treatment consists of neoadjuvant sequential chemotherapy, HER2-targeted therapy, surgery, and, if indicated, radiotherapy and/or hormonal therapy. Trastuzumab, a recombinant antibody targeting HER2, has significantly extended the overall survival of BC patients and remains clinically reliable treatment. The 5-year survival, when following the standard treatment protocol, including HER2-targeted therapy, leads to a favorable prognosis with a 5-year survival rate around 75%. Improved overall survival (OS) was reported in BC patients when trastuzumab was administered in both the neoadjuvant and adjuvant period rather than in the adjuvant period alone. Thus, trastuzumab-containing neoadjuvant therapy is currently the standard of care [1].

A recent study performed by Ignatov et al. [2] investigated whether the loss of HER2 expression is related to trastuzumab treatment. The cohort consisted of 227 patients, in which second biopsy could be...


Compliance with ethical standards

Conflict of interest

The authors Zuzana Strizova, Jiri Vachtenheim Jr., and Jirina Bartunkova declare that there is no conflict of interest regarding the publication of this article. The manuscript has been approved for publication by all authors and is not currently under review or submitted to another journal.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors Zuzana Strizova, Jiri Vachtenheim Jr. and Jirina Bartunkova.

Research involving human and animal participants

Humans were not involved in the study.


  1. 1.
    Echavarria I, Granja M, Bueno C, Lopez-Tarruella S, Peinado P, Sotelo M et al (2017) Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. Breast Cancer Res Treat 162(1):181–189CrossRefGoogle Scholar
  2. 2.
    Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A (2019) Loss of HER2 after HER2-targeted treatment. Breast Cancer Res Treat 175(2):401–408CrossRefGoogle Scholar
  3. 3.
    Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ et al (2018) Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep 23(13):3946–3959.e6CrossRefGoogle Scholar
  4. 4.
    Valgardsdottir R, Cattaneo I, Klein C, Introna M, Figliuzzi M, Golay J (2017) Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. Blood 129(19):2636–2644CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.First Faculty of Medicine and Second Faculty of MedicineCharles University in Prague and Motol University HospitalPrague 5Czech Republic
  2. 2.Department of Immunology, Second Faculty of MedicineCharles University in Prague and Motol University HospitalPrague 5Czech Republic
  3. 3.Third Department of Surgery, First Faculty of MedicineCharles University in Prague and Motol University HospitalPrague 5Czech Republic

Personalised recommendations